Holen Sie sich die Stockscreener-App
28.51
0.39%
0.11
Handel nachbörslich:
28.51
Schlusskurs vom Vortag:
$28.40
Offen:
$28.04
24-Stunden-Volumen:
950.54K
Relative Volume:
0.55
Marktkapitalisierung:
$4.56B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-9.3783
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
-0.59%
1M Leistung:
-13.37%
6M Leistung:
-26.90%
1J Leistung:
-29.92%
1-Tages-Spanne:
$27.90
$29.06
1-Wochen-Bereich:
$27.57
$29.06
52-Wochen-Spanne:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
28.51 | 4.56B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way? - simplywall.st
Ionis Pharmaceuticals EVP Jenne Kyle sells $85,533 in stock - Investing.com Australia
Ionis Pharmaceuticals EVP Jenne Kyle sells $85,533 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals EVP Brian Birchler sells $19,291 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP Joseph Baroldi sells $111,555 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP Joseph Baroldi sells $111,555 in stock - Investing.com
Lobbying Update: $90,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
Ionis to hold first quarter 2025 financial results webcast - BioSpace
Ionis Q1 2025 Earnings Call: Key Date and Details for Investors Revealed - Stock Titan
Ionis Pharmaceuticals (IONS) Sees Price Target Cut by Morgan Sta - GuruFocus
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains? - MSN
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
Global Antisense & RNAi Therapeutics Market to Witness Massive - openPR.com
Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com
Transthyretin Amyloid Cardiomyopathy Treatment Market Set - openPR.com
Ionis at Needham Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com UK
Ionis Pharmaceuticals initiated with a Buy at H.C. Wainwright - MSN
HC Wainwright & Co. Initiates Coverage of Ionis Pharmaceuticals (IONS) with Buy Recommendation - MSN
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' - Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Ionis Pharma stock hits 52-week low at $26.65 amid market challenges - Investing.com
H.C. Wainwright initiates coverage for Ionis Pharma with 'buy' rating citing pending drug launches - TradingView
H.C. Wainwright initiated coverage on Ionis Pharma with a new price target - Quantisnow
HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target - MarketScreener
H.C. Wainwright sets Ionis stock Buy rating, $45 target By Investing.com - Investing.com UK
Ionis Pharmaceuticals Enters Oversold Territory (IONS) - Nasdaq
Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com
Ionis to host expert panel discussion on sHTG - The Joplin Globe
Leading Medical Experts Reveal Latest Insights on Severe HTG Treatment Landscape - Stock Titan
Treatment-resistant Hypertension Market Growth Projections 2024-2034: DelveInsight Analysis | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics - Barchart.com
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease - Biogen
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
Redburn Atlantic Initiates Coverage of Ionis Pharmaceuticals (IONS) with Neutral Recommendation - MSN
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts - Benzinga
Redburn Atlantic initiated coverage on Ionis Pharma with a new price target - Quantisnow
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target - MarketScreener
Ionis to present at upcoming investor conferences - The Joplin Globe
Redburn initiates Ionis stock with Neutral, sets $39 target - Investing.com India
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi - MSN
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - MSN
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
RNA Biotechs: Current State And Outlook - Seeking Alpha
Ionis and Sobi agree on olezarsen commercialisation - Yahoo
Ionis licenses olezarsen to Sobi for global reach By Investing.com - Investing.com South Africa
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):